Related Experiment Video
Updated: Aug 4, 2025
10:24
Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
Published on: February 12, 2018
10.2K
Randomized controlled trials in central serous chorioretinopathy: A review
Sumit Randhir Singh1,2, John Thomas Goté3, Jay Chhablani4
1Sri Sai Eye Hospital, Kankarbagh, Patna, Bihar, India.
Eye (London, England)
|March 30, 2023
Summary
Central serous chorioretinopathy (CSCR) lacks standardized treatment protocols and randomized controlled trials. Reviewing existing literature highlights inconsistencies that hinder progress toward a consensus-based approach for this common chorioretinal disease.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Chorioretinal Disorders
Background:
- Central serous chorioretinopathy (CSCR) is a common chorioretinal disease with diverse clinical presentations, from acute neurosensory detachment to chronic RPE changes and choroidal neovascularization (CNV).
- Variable natural history of CSCR often leads to suboptimal visual outcomes.
- Despite available treatments like laser, PDT, anti-VEGF, and systemic drugs, no standardized protocol or gold standard exists, and their efficacy versus observation remains debated.
Purpose of the Study:
- To analyze and compare existing literature on Central serous chorioretinopathy (CSCR) to identify discrepancies in study designs.
- To highlight the relative lack of randomized controlled trials (RCTs) in CSCR compared to other retinal diseases.
- To provide recommendations for standardizing future study designs to facilitate a consensus-based treatment protocol.
Main Methods:
- Literature review of published papers on Central serous chorioretinopathy (CSCR).
- Analysis and comparison of study inclusion criteria, imaging modalities, endpoints, duration, and results.
- Identification of inconsistencies and deficiencies in current research methodologies.
Main Results:
- A significant dearth of randomized controlled trials (RCTs) exists for CSCR.
- Inconsistencies in disease duration reporting, inclusion criteria, outcome measures, and treatment modalities complicate RCT design.
- Existing literature analysis reveals variability that prevents the establishment of a consensus-based treatment protocol.
Conclusions:
- Standardizing future study designs by correcting current discrepancies is crucial for advancing Central serous chorioretinopathy (CSCR) research.
- Addressing methodological inconsistencies will facilitate the development of a much-needed standardized treatment protocol.
- Improved study design will ultimately lead to better management and visual outcomes for patients with CSCR.
Related Concept Videos
01:27Open Angle Glaucoma: Treatment
505
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
505
01:28Angle Closure Glaucoma: Treatment
590
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
590